Background. Opioids represent the mainstay for treating postsurgical pain but can cause significant morbidity in addition to dependency. The aim of the study was to determine the incidence of persistent opioid use after lung surgery.
Background. Opioids represent the mainstay for treating postsurgical pain but can cause significant morbidity in addition to dependency. The aim of the study was to determine the incidence of persistent opioid use after lung surgery.
Methods. Patients who underwent lung resection from 2008 to 2013 for non-small cell lung cancer were identified in the Surveillance, Epidemiology and End Results-Medicare database. Patients were categorized as being chronic, intermittent, or naïve preoperative opioid users using information obtained from part D records. Persistent opioid use was defined as having a filled opioid prescription between 3 and 6 months after lung resection.
Results. A total of 6948 patients were identified, among whom 3946 (56.8%) were opioid naïve, 2017 (29.0%) were intermittent opioid users, and 985 (14.2%) were chronic opioid users preoperatively. Persistent opioid use (3-6 months) after lung resection was high (31%), even among opioid-naïve patients (17%). Among those who were previously opioid naïve, independent predictors of persistent opioid use were receipt of adjuvant radiation or chemotherapy, less than 70 years of age, Charlson comorbidity score of 1 or 2, and residence in zip codes associated with lower education. Conversely, patients who underwent minimally invasive surgery were less likely to have persistent opioid use. Those with persistent opioid use after surgery did not show any trend toward returning to preoperative opioid utilization for at least the first postoperative year.
Conclusions. Opioid dependence after lung resection in the population over 65 years of age is high but was significantly lower among those who received minimally invasive surgery, in addition to other factors.
(Ann Thorac Surg 2020;109:194-202) Ó 2020 by The Society of Thoracic Surgeons F or many years, opioids have represented the mainstay of treating postsurgical pain, driven in large part by their remarkable analgesic efficacy and ease of use. In addition, among some patients, opioids may allow a high quality of life and allow one to maintain function. However, postoperative morbidity related to opioid therapy can be severe. [1] [2] [3] [4] [5] [6] Furthermore, chronic use may develop, which is helping to fuel the opioid crisis. 7 From 2001 to 2016, opioid-related deaths in the United States increased 345%. 8 Although the current opioid crisis appears to be affecting the surgical and nonsurgical population, those who receive lung surgery are at a heightened risk of chronic opioid use a year after surgery relative to those who receive surgical procedures at other sites. 9, 10 Approximately 1 in 10 patients continue to report moderate to severe pain a year after lung resection, which is lower among those who receive video-assisted thoracoscopic surgery. 11 The aim of our current study was to determine the incidence of persistent opioid use after lung surgery and predictors of persistent opioid use. We hypothesized that minimally invasive surgery, by virtue of lessened operative trauma and improved postoperative pain, would be associated with a decreased incidence of opioid dependence. cancer incidence and survival data from several population based cancer registries and is supported by the National Cancer Institute. 13 Overall, the SEER database covers approximately 35% of the U.S. population. In addition, Medicare eligibility extends to 97% of those 65 years of age and older, with claims data available among those who have fee for service. 12 The linkage resulted in 93% of persons 65 years of age and older within the SEER database being matched to the Medicare enrollment file. An estimated 60% of Medicare beneficiaries are also covered by part D, which provides additional coverage for prescription drugs.
Selection Criteria
Patients who were over 65 years of age and underwent resection of non-small cell lung cancer (NSCLC) between 2008 and 2013 were selected for analysis. NSCLC was identified using International Classification of Diseases for Oncology-Third Revision histology codes (Appendix). Patients were required to be enrolled in parts A and B of Medicare during the 12 months before surgery or 9 months after surgery and to not be enrolled in an health maintenance organization during this time, to ensure complete claims data. Furthermore, to ensure complete prescription records, patients were required to be enrolled in part D for 12 months before and at least 12 months after surgery. Diagnosis was required to be as follows: required to have histologic confirmation, undergo surgery within 6 months of diagnosis or be diagnosed as late as 30 days after surgery, with exclusion of those diagnosed at autopsy or death certificate. NSCLC was identified using International Classification of Diseases for Oncology-Third Revision histology codes (Appendix).
Variable Definitions
Charlson comorbidity scores were calculated using MEDPAR (Medicare Provider Analysis and Review), National Claims History, and outpatient claims 1 year before surgery using the Klabunde algorithm. 14, 15 Opioid use was determined using part D records, which include the name of prescribed opioid as well as the dose and quantity filled. In terms of preoperative opioid use, we categorized patients as being opioid naïve, an intermittent opioid user, or a chronic opioid user according to previously utilized criteria. 7 We defined opioid-naïve patients as those who had no opioid prescriptions between 31 days to 12 months before surgery. We defined chronic opioid users as those who had at least 120 cumulative days of supply between 31 days and 12 months before surgery, similar to prior definitions. We defined intermittent opioid users as those not meeting either definition. Medicare claims were used to identify adjuvant chemotherapy and radiation therapy. The sixth edition of the American Joint Committee on Cancer Staging Manual was used for staging purposes, which represents the best of pathologic or clinical staging. Census data corresponding to the zip code of residence of the patient were used to identify the education level and the poverty level. Cells with counts less than 11 were suppressed to protect the confidentiality of Medicare beneficiaries, according to SEER-Medicare requirements.
Statistical Analysis
Patient, tumor, and operative variables were compared using the chi-square test or Fisher's exact test, where appropriate. To determine factors associated with persistent opioid use 3 to 6 months after surgery, a logistic regression model was utilized using an a priori selected model. All factors selected for univariable analysis were included in the multivariable model. The quantity of the opioid filled was multiplied by the oral morphine equivalent (OME) of each opioid to calculate the mean total monthly OME. The Wilcoxon signed rank test was used to compare monthly OME utilization. All statistical tests were 2-sided, and P < .05 was considered statistically significant. Statistical analysis was performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results

Demographics and Incidence of Persistent Opioid Use
A total of 6948 patients were identified from the SEER-Medicare database as having undergone lung resection for NSCLC between 2008 and 2013 ( Figure 1 ). Complete patient, tumor, and operative characteristics of the identified cohort are shown in Table 1 . The incidence of persistent opioid use 3 to 6 months after surgery was 2152 of 6948 (31%) patients, and remained elevated among those who were previously opioid naïve (654 of 3946 patients, 17%).
Reduction in Persistent Opioid Use Among Those Who Receive Video-Assisted Thoracoscopic Surgery
Among patients who were previously opioid naïve, we identified that receiving adjuvant radiation (adjusted odds ratio [OR], 1.36; 95% confidence interval [CI], 1.06-1.74) or chemotherapy (OR, 1.87; 95% CI, 1.49-2.33) was independently associated with an increased risk of persistent opioid use 3 to 6 months after surgery ( Table 2) . Additional factors associated with increased risk included less than 70 years of age (OR, 1.55; 95% CI, 1.16-2.06), Charlson comorbidity score of 1 (OR, 1.35; 95% CI, 1.10-1.64) or 2 (OR, 1.27; 95% CI, 1.00-1.60), and residence in zip codes associated with lower education (OR, 1.86; 95% CI, 1.32-2.61). However, patients who underwent minimally invasive surgery were less likely to have persistent opioid use (OR, 0.75; 95% CI, 0.62-0.90) after adjusting for other factors. Additional factors that were significant on univariable only but were no longer significant predictors on multivariable analysis included race, urban environment, poverty level, stage, extent of resection, and tumor grade.
Opioid Utilization Remains Elevated Among Persistent Users: A New Baseline?
Opioid utilization for the year leading up to lung resection and for the year after surgery is shown in Figure 2 . Among those who were intermittent opioid users preoperatively and developed persistent opioid use, the mean monthly OME utilization 12 months after surgery was significantly higher as compared with preoperative use (P < .001). Opioid utilization among previously opioid-naïve or previously intermittent opioid users who became persistent opioid users did not significantly change between months 6 and 12, and did not display any trend toward returning to preoperative levels. Last, patients with chronic opioid use showed no significant change in opioid utilization a year after surgery as compared with baseline levels (P ¼ .660).
Comment
We found that a high number of patients (1 in 3) continue to fill opioid prescriptions 3 to 6 months after lung resection. Factors associated with persistent opioid use among previously opioid-naïve patients included younger age, comorbidity, sociodemographic factors, and receiving adjuvant therapy. Conversely, receiving minimally invasive surgery was associated with less persistent opioid use. Among persistent opioid users, opioid use between months 6 and 12 shows no trend toward returning toward preoperative levels.
Prior studies have shown that the risk of chronic opioid use is elevated among patients who have surgery, 16 especially among those who have major surgery. 10, 16 Unfortunately, lung surgery has been identified as one of the highest contributors toward chronic opioid use. 10 Although persistent opioid use may have a role for some patients to allow function and maintain quality of life, opioid use has been shown to be associated with several deleterious aspects of health. These include overdose, 17 poor compliance with treatment recommendations, 18 operative morbidity and mortality, 1-6 and risk of subsequent opioid dependence for family members, 19 among many others.
In our study, minimally invasive surgery was associated with a decreased incidence of persistent opioid use, suggesting that expanding the use of minimally invasive surgery may help decrease opioid utilization. Our finding is supported by a number of studies that have shown that minimally invasive surgery is less painful, including a well-regarded randomized trial. 11 Patients who receive a thoracotomy traditionally receive an epidural or opioid pump to treat postoperative pain. However, we found that after we implemented an enhanced recovery pathway, which incorporates multimodal analgesia techniques including a liposomal bupivacaine block, that thoracotomy was no longer associated with worse pain scores or opioid utilization. 20 We also found that postoperative morbidity was improved for patients who receive a thoracotomy, suggesting that many of the deleterious impacts of thoracotomy were lessened. 21 Other centers have similarly found a reduction in opioid usage and also hospital costs after implementation of an enhanced recovery program. 22 This suggests that the results of this present study may not be generalizable to centers experienced in enhanced recovery including multimodal analgesia.
Several other interventions in addition to enhanced recovery protocols may be helpful toward decreasing opioid use. Although several randomized trials have shown no difference with regard to pain scores among thoracotomy patients who are randomized to receive gabapentin to varying amounts, [23] [24] [25] a recent randomized trial that included thoracotomy patients indicated that patients assigned to perioperative gabapentin were more likely to stop using opioids after surgery. 26 Perhaps related to the efficacy of gabapentin toward opioid cessation, intercostal nerve injury has been implicated a likely cause of chronic postthoracotomy pain. [27] [28] [29] [30] Observational studies have also found associations between postoperative prescriptions with subsequent opioid use 31, 32 and have highlighted a significant level of variability in opioid prescribing practices. 33 In addition, an intervention to lower the default pill counts in an electronic medical record system was associated with a decrease in opioid prescription quantity. 34 However, it remains to be seen whether changing postoperative opioid prescribing patterns may in turn improve chronic opioid use.
Limitations
Limitations of this retrospective study include the risk of confounding. First, although we adjusted for detailed sociodemographic, patient-related, and tumor-related factors, those who received minimally invasive surgery may still represent different kinds of patients from those who received open surgery. We were additionally unable to identify the reason for opioid use. Second, our study highlights nationwide opioid utilization and includes patients treated under traditional care pathways. As mentioned previously, a prior study by our institution showed no difference in opioid utilization between those who received minimally invasive surgery and those who received a thoracotomy when patients were treated with multimodal analgesia including a liposomal bupivacaine block. Third, owing to our study design, we restricted our analysis to patients who had complete part D records for a year after surgery, which in turn excludes those who suffered a perioperative mortality or died in the first year. Therefore, our results are not generalizable to those who did not survive for at least a year after surgery.
Conclusion
We found that the incidence of persistent opioid use after lung resection is high. Factors associated with persistent opioid use among previously opioid-naïve patients included age, Charlson comorbidity score, sociodemographic factors, and adjuvant therapy. We also caution that receiving a thoracotomy was also associated with an increased risk of persistent opioid use in our present analysis. Further interventions to decrease the risk of persistent opioid use among thoracotomy patients should be investigated, and as highlighted previously, may include use of multimodal analgesia.
